Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC) - Trial NCT06361043
Access comprehensive clinical trial information for NCT06361043 through Pure Global AI's free database. This phase not specified trial is sponsored by Insel Gruppe AG, University Hospital Bern and is currently Recruiting. The study focuses on Esophageal Cancer. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Insel Gruppe AG, University Hospital Bern
Timeline & Enrollment
N/A
Apr 20, 2024
Feb 28, 2027
Primary Outcome
Number of patients with pulmonary toxicity
Summary
Despite multimodal therapy, patients with esophageal cancer have poor prognosis with 5-year
 overall survival around 25%. Considering tumor-related death as main reason for high
 mortality rate in those patients, treatment-related cardio-pulmonary toxicities could also
 play a role in this regard. Online adaptive radiotherapy offers the possibility for daily
 re-planning and therefore helps radiation oncologists to better spare the organs at risk and
 reduce radiation-induced toxicity. Tha aim of ARTEC is to assess the pulmonary toxicity in
 patients with esophageal cancer treated with online adaptive radiotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06361043
Non-Device Trial